|
業務類別
|
Biotechnology |
|
業務概覽
|
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cellline development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval. |
| 公司地址
| 18105 SE Mill Plain Boulevard, Vancouver, WA, USA, 98683 |
| 電話號碼
| +1 360 949-1041 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.absci.com |
| 員工數量
| 140 |
| Mr. Todd Bedrick |
Chief Accounting Officer |
-- |
24/03/2026 |
| Dr. Ransi Somaratne, M.D. |
Chief Medical Officer |
-- |
06/03/2026 |
| Mr. Sean McClain |
Chief Executive Officer and Director |
美元 689.94K |
22/04/2026 |
| Dr. Zachariah Jonasson, PhD |
Chief Financial Officer and Chief Business Officer |
美元 553.45K |
22/04/2026 |
| Ms. Shelby J. Walker, J.D.,M.S. |
Chief Legal Officer |
-- |
22/04/2026 |
|
|
| Ms. Mary T. Szela |
Director |
22/04/2026 |
| Ms. Karen K. McGinnis, C.P.A. |
Independent Director |
22/04/2026 |
| Professor Menelas Pangalos, PhD |
Independent Director |
22/04/2026 |
| Mr. Joseph Sirosh, PhD |
Independent Director |
22/04/2026 |
| Mr. Daniel A. Rabinovitsj |
Independent Director |
22/04/2026 |
| Mr. Frans Van Van Houten, M.Sc. |
Chairman of the Board |
22/04/2026 |
| Mr. Sean McClain |
Chief Executive Officer and Director |
22/04/2026 |
|
|
|
|
